Safety concerns with J&J's COVID-19 vaccine present a big opportunity for Pfizer, Moderna: analyst

The advantage, now, goes to Moderna and Pfizer-BioNTech, a biopharma analyst writes.

With mRNA vaccines further ahead in their rollouts and no safety issues cropping up so far, those programs are in a prime position to benefit, Cantor Fitzgerald analyst Louise Chen wrote to clients on Wednesday.